MAPK7 and breast cancer: Unlike other ERK5 inhibitors, which frequently failed to mimic ERK5 genetic ablation phenotypes.BAY-885 treatment could recapitulate ERK5 depletion effects, and genetically-induced activation of constitutively activated ERK5 abrogated the effects of BAY-885 in BC cells.